{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:38:44Z","timestamp":1794335924080,"version":"4.9.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cgfr.co.uk","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine & Growth Factor Reviews"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.cytogfr.2014.07.015","type":"journal-article","created":{"date-parts":[[2014,7,28]],"date-time":"2014-07-28T22:22:38Z","timestamp":1406586158000},"page":"369-376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":240,"title":["Interferons: Success in anti-viral immunotherapy"],"prefix":"10.1016","volume":"25","author":[{"given":"Fan-ching","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard A.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cytogfr.2014.07.015_bib0005","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev.immunol.23.021704.115843","article-title":"Type I interferons (alpha\/beta) in immunity and autoimmunity","volume":"23","author":"Theofilopoulos","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0010","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nri3133","article-title":"Immunomodulatory functions of type I interferons","volume":"12","author":"Gonzalez-Navajas","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0020","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.immuni.2006.08.014","article-title":"Complex modulation of cell type-specific signaling in response to type I interferons","volume":"25","author":"van Boxel-Dezaire","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0025","doi-asserted-by":"crossref","first-page":"580968","DOI":"10.1155\/2013\/580968","article-title":"Interferon at the interface of antiviral immunity and immune regulation: the curious case of HIV-1","volume":"2013","author":"Boasso","year":"2013","journal-title":"Scientifica"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0030","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.immuni.2006.08.007","article-title":"Type I interferons in host defense","volume":"25","author":"Stetson","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0035","doi-asserted-by":"crossref","first-page":"30ra2","DOI":"10.1126\/scitranslmed.3000544","article-title":"Rapid emergence of protease inhibitor resistance in hepatitis C virus","volume":"2","author":"Rong","year":"2010","journal-title":"Sci Transl Med"},{"issue":"Suppl 1","key":"10.1016\/j.cytogfr.2014.07.015_bib0040","first-page":"23","article-title":"Pharmacokinetics of peginterferons","volume":"23","author":"Zeuzem","year":"2003","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0045","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/nrgastro.2010.101","article-title":"Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C","volume":"7","author":"Aghemo","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0050","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/bph.12010","article-title":"IFN-alpha subtypes: distinct biological activities in anti-viral therapy","volume":"168","author":"Gibbert","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0055","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1517\/14712598.2011.552906","article-title":"Interferon in the treatment of chronic hepatitis C: a drug caught between past and future","volume":"11","author":"Vezali","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0060","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nrgastro.2011.21","article-title":"Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C","volume":"8","author":"Sulkowski","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0065","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.pep.2008.04.013","article-title":"Increasing the homogeneity, stability and activity of human serum albumin and interferon-alpha2b fusion protein by linker engineering","volume":"61","author":"Zhao","year":"2008","journal-title":"Protein Expr Purif"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0070","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/135965350601100111","article-title":"A Phase I\/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy","volume":"11","author":"Balan","year":"2006","journal-title":"Antivir Ther"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0075","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1053\/j.gastro.2010.06.066","article-title":"Albinterferon Alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 1","volume":"139","author":"Zeuzem","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0080","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/hep.22871","article-title":"Retreating chronic hepatitis C with daily interferon alfacon-1\/ribavirin after nonresponse to pegylated interferon\/ribavirin: direct results","volume":"49","author":"Bacon","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0085","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1007\/s10620-007-9757-9","article-title":"Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin","volume":"52","author":"Sjogren","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0090","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/clpt.2013.206","article-title":"Novel therapeutic approaches for hepatitis C","volume":"95","author":"Au","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0095","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1146\/annurev-pharmtox-011112-140254","article-title":"Direct-acting antiviral agents for hepatitis C virus infection","volume":"53","author":"Kiser","year":"2013","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0100","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","article-title":"Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures","volume":"11","author":"Lavanchy","year":"2004","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0105","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrgastro.2011.33","article-title":"Hepatitis B therapy","volume":"8","author":"Kwon","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2014.04.004","article-title":"Immunotherapeutic interventions in chronic Hepatitis B virus infection: a review","author":"Wang","year":"2014","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0115","unstructured":"Organization WH. Hepatitis B."},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0120","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/hepr.12058","article-title":"Interferon-alpha plus adefovir combination therapy versus interferon-alpha monotherapy for chronic hepatitis B treatment: a meta-analysis","volume":"43","author":"Huang","year":"2013","journal-title":"Hepatol Res: Off J Jpn Soc Hepatol"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0125","first-page":"680","article-title":"Improved efficacy by individualized combination therapy with Peg IFN-a 2a and ADV in HBeAg positive chronic hepatitis B patients","volume":"59","author":"Wang","year":"2012","journal-title":"Hepato-gastroenterology"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0130","first-page":"1165","article-title":"Peginterferon-alpha2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study","volume":"25","author":"Huang","year":"2013","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0135","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1365-2893.2010.01332.x","article-title":"Sequential therapy with adefovir dipivoxil and pegylated interferon alfa-2a for HBeAg-negative patients","volume":"18","author":"Moucari","year":"2011","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0140","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3851\/IMP2281","article-title":"A randomized controlled trial of sequential pegylated interferon-alpha and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B","volume":"18","author":"Piccolo","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0145","doi-asserted-by":"crossref","first-page":"20","DOI":"10.5009\/gnl.2009.3.1.20","article-title":"Recombinant interferon-Beta-1alpha plus ribavirin for the treatment of chronic HCV infection: a prospective, randomized, comparative pilot study","volume":"3","author":"Ahn","year":"2009","journal-title":"Gut Liver"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0150","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.transproceed.2008.10.056","article-title":"Efficacy of interferon Beta combined with cyclosporine induction and intensified therapy for retreatment of chronic hepatitis C","volume":"41","author":"Inoue","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0155","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/j.1872-034X.2012.00995.x","article-title":"Efficacy of the regimen using twice-daily beta-interferon followed by the standard of care for chronic hepatitis C genotype 1b with high viral load","volume":"42","author":"Ishikawa","year":"2012","journal-title":"Hepatol Res: Off J Jpn Soc Hepatol"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0160","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/jgh.12039","article-title":"Lead-in treatment with interferon-beta\/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b\/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype","volume":"28","author":"Itokawa","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0165","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/0264-410X(94)90116-3","article-title":"Randomized comparative trial of interferon-alpha versus placebo in hepatitis B vaccine non-responders and hyporesponders","volume":"12","author":"Goldwater","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0170","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.vaccine.2007.12.044","article-title":"Evaluation of the effects of human leukocyte IFN-alpha on the immune response to the HBV vaccine in healthy unvaccinated individuals","volume":"26","author":"Rizza","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0175","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cytogfr.2009.02.006","article-title":"Structural conservation of interferon gamma among vertebrates","volume":"20","author":"Savan","year":"2009","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0180","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1189\/jlb.0603252","article-title":"Interferon-gamma: an overview of signals, mechanisms and functions","volume":"75","author":"Schroder","year":"2004","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cyto.2009.11.021","article-title":"Gene modulation and immunoregulatory roles of interferon gamma","volume":"50","author":"Saha","year":"2010","journal-title":"Cytokine"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0190","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cytogfr.2008.08.004","article-title":"IFNgamma signaling-does it mean JAK-STAT?","volume":"19","author":"Gough","year":"2008","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0195","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3389\/fimmu.2013.00202","article-title":"IFN signaling: how a non-canonical model led to the development of IFN mimetics?","volume":"4","author":"Johnson","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0200","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3389\/fimmu.2013.00498","article-title":"The Significance of Interferon-gamma in HIV-1 pathogenesis, therapy, and prophylaxis","volume":"4","author":"Roff","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0205","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/QAD.0b013e3283536a93","article-title":"Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial","volume":"26","author":"Jarvis","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0210","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/jgh.12060","article-title":"Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI)","volume":"28","author":"Couzigou","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0215","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1499-3872(11)60024-6","article-title":"Long-term antifibrotic action of interferon-gamma treatment in patients with chronic hepatitis B virus infection","volume":"10","author":"Wu","year":"2011","journal-title":"Hepatobiliary Pancreat Dis Int: HBPD INT"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0220","doi-asserted-by":"crossref","first-page":"20869","DOI":"10.1074\/jbc.M109.002923","article-title":"Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family","volume":"284","author":"Gad","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0225","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/gene.2009.72","article-title":"Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines","volume":"10","author":"Witte","year":"2009","journal-title":"Genes Immun"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0230","doi-asserted-by":"crossref","first-page":"32269","DOI":"10.1074\/jbc.M404789200","article-title":"Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29\/interferon-lambda 1: similarities with type I interferon signaling","volume":"279","author":"Dumoutier","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0235","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/hep.21312","article-title":"Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes","volume":"44","author":"Doyle","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0240","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1128\/JVI.79.6.3851-3854.2005","article-title":"Lambda interferon inhibits hepatitis B and C virus replication","volume":"79","author":"Robek","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0245","doi-asserted-by":"crossref","first-page":"e35902","DOI":"10.1371\/journal.pone.0035902","article-title":"IFN-lambda3 inhibits HIV infection of macrophages through the JAK\u2013STAT pathway","volume":"7","author":"Liu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0250","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.antiviral.2012.04.011","article-title":"IFN-lambda inhibits HIV-1 integration and post-transcriptional events in vitro, but there is only limited in vivo repression of viral production","volume":"95","author":"Tian","year":"2012","journal-title":"Antivir Res"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0255","doi-asserted-by":"crossref","first-page":"e1000017","DOI":"10.1371\/journal.ppat.1000017","article-title":"IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo","volume":"4","author":"Sommereyns","year":"2008","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0260","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.bbrc.2005.04.004","article-title":"SOCS-1 inhibits expression of the antiviral proteins 2\u2019,5\u2019-OAS and MxA induced by the novel interferon-lambdas IL-28A and IL-29","volume":"331","author":"Brand","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0265","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/ni875","article-title":"IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex","volume":"4","author":"Kotenko","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0270","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/hep.23743","article-title":"Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection","volume":"52","author":"Muir","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0275","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1089\/jir.2010.0066","article-title":"Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C","volume":"30","author":"Ramos","year":"2010","journal-title":"J Interferon Cytokine Res: Off J Int Soc Interferon Cytokine Res"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0280","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.it.2011.07.002","article-title":"Interferon-lambda and therapy for chronic hepatitis C virus infection","volume":"32","author":"Donnelly","year":"2011","journal-title":"Trends Immunol"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0285","unstructured":"Elicker J. Investigational compound PEG-interferon lambda achieved higher response rates with fewer flu-like and musculoskeletal symptoms and cytopenias than PEG-interferon alfa in Phase IIb study of 526 treatment-naive Hepatitis C patients; 2011."},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0290","doi-asserted-by":"crossref","first-page":"847545","DOI":"10.1155\/2014\/847545","article-title":"Interferons: key players in normal skin and select cutaneous malignancies","volume":"2014","author":"Ismail","year":"2014","journal-title":"Dermatol Res Pract"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0295","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.4049\/jimmunol.1290060","article-title":"IFN-alpha in the treatment of melanoma","volume":"189","author":"Tarhini","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0300","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.eururo.2012.08.027","article-title":"Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY)","volume":"63","author":"Bracarda","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0305","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s12094-012-0991-z","article-title":"Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib in renal cell carcinoma (RCC)","volume":"15","author":"Maroto","year":"2013","journal-title":"Clin Transl Oncol: Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0310","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1093\/annonc\/mdt228","article-title":"A multinational phase II trial of bevacizumab with low-dose interferon-alpha2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN","volume":"24","author":"Melichar","year":"2013","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol\/ESMO"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0315","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1200\/JCO.2013.50.5305","article-title":"Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial","volume":"32","author":"Rini","year":"2014","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0320","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1002\/cncr.28328","article-title":"Tolerability and efficacy of pegylated interferon-alpha-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia","volume":"119","author":"Johnson-Ansah","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0325","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","article-title":"Combination of pegylated IFN-alpha2b with imatinib increases molecular response rates in patients with low or intermediate-risk chronic myeloid leukemia","volume":"118","author":"Simonsson","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0330","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/leu.2012.313","article-title":"Re-emergence of interferon-alpha in the treatment of chronic myeloid leukemia","volume":"27","author":"Talpaz","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0335","first-page":"149","article-title":"The molecular study of IFNbeta pleiotropic roles in MS treatment","volume":"12","author":"Kay","year":"2013","journal-title":"Iran J Neurol"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0340","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11940-013-0233-x","article-title":"Management of secondary progressive multiple sclerosis: prophylactic treatment-past, present, and future aspects","volume":"15","author":"Rommer","year":"2013","journal-title":"Curr Treat Option Neurol"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0345","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s12016-010-8226-y","article-title":"Therapeutic perspectives in atopic dermatitis","volume":"41","author":"Misery","year":"2011","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.cytogfr.2014.07.015_bib0350","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1086\/422993","article-title":"Long-term interferon-gamma therapy for patients with chronic granulomatous disease","volume":"39","author":"Marciano","year":"2004","journal-title":"Clin Infect Dis: Off Publ Infect Dis Soc Am"}],"container-title":["Cytokine & Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135961011400077X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135961011400077X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T10:43:13Z","timestamp":1717152193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135961011400077X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S135961011400077X"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2014.07.015","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interferons: Success in anti-viral immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2014.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}